MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Free Report) CEO Da Silva Jorge Santos sold 47,775 shares of the company’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $20.03, for a total value of $956,933.25. Following the transaction, the chief executive officer directly owned 2,877,118 shares of the company’s stock, valued at $57,628,673.54. The trade was a 1.63% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Da Silva Jorge Santos also recently made the following trade(s):
- On Monday, April 13th, Da Silva Jorge Santos sold 51,873 shares of MoonLake Immunotherapeutics stock. The stock was sold at an average price of $18.23, for a total value of $945,644.79.
- On Friday, April 10th, Da Silva Jorge Santos sold 98,127 shares of MoonLake Immunotherapeutics stock. The stock was sold at an average price of $18.41, for a total transaction of $1,806,518.07.
MoonLake Immunotherapeutics Stock Down 0.9%
MoonLake Immunotherapeutics stock traded down $0.18 during mid-day trading on Thursday, reaching $18.95. The stock had a trading volume of 1,391,554 shares, compared to its average volume of 1,547,101. The company has a 50-day moving average price of $18.26 and a two-hundred day moving average price of $17.00. MoonLake Immunotherapeutics has a one year low of $5.95 and a one year high of $62.75. The company has a debt-to-equity ratio of 0.39, a current ratio of 8.60 and a quick ratio of 8.60. The company has a market capitalization of $1.39 billion, a price-to-earnings ratio of -4.90 and a beta of 1.04.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently made changes to their positions in the stock. Avidity Partners Management LP acquired a new position in MoonLake Immunotherapeutics in the first quarter valued at approximately $932,000. Bank of America Corp DE increased its position in shares of MoonLake Immunotherapeutics by 5,255.8% during the first quarter. Bank of America Corp DE now owns 724,794 shares of the company’s stock worth $13,510,000 after acquiring an additional 711,261 shares during the period. Janus Henderson Group PLC raised its position in MoonLake Immunotherapeutics by 64.7% in the 1st quarter. Janus Henderson Group PLC now owns 3,451,628 shares of the company’s stock valued at $64,304,000 after purchasing an additional 1,355,640 shares in the last quarter. EverSource Wealth Advisors LLC grew its holdings in MoonLake Immunotherapeutics by 221.1% during the 1st quarter. EverSource Wealth Advisors LLC now owns 2,867 shares of the company’s stock worth $53,000 after acquiring an additional 1,974 shares in the last quarter. Finally, Readystate Asset Management LP acquired a new stake in MoonLake Immunotherapeutics in the first quarter valued at $2,689,000. 93.85% of the stock is currently owned by institutional investors and hedge funds.
Analyst Ratings Changes
A number of research analysts have recently weighed in on the company. HC Wainwright restated a “buy” rating and set a $45.00 price objective on shares of MoonLake Immunotherapeutics in a research report on Monday, June 8th. BTIG Research reiterated a “buy” rating and set a $30.00 price objective on shares of MoonLake Immunotherapeutics in a report on Tuesday, June 9th. Needham & Company LLC raised their target price on shares of MoonLake Immunotherapeutics from $25.00 to $30.00 and gave the company a “buy” rating in a research report on Tuesday, May 12th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of MoonLake Immunotherapeutics in a research report on Tuesday, May 12th. Finally, Rothschild & Co Redburn upgraded MoonLake Immunotherapeutics from a “neutral” rating to a “buy” rating and increased their price objective for the company from $12.00 to $40.00 in a report on Thursday, March 19th. Ten investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, MoonLake Immunotherapeutics currently has a consensus rating of “Hold” and a consensus target price of $24.21.
View Our Latest Stock Analysis on MLTX
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.
Featured Stories
- Five stocks we like better than MoonLake Immunotherapeutics
- Shorting the Grid: Bloom Energy’s $25B AI Power Play
- SanDisk’s Volatility May Be Telling Bulls What They Want to Hear
- Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon
- 3 Dividend ETFs Built for Stability in a Volatile Market
Receive News & Ratings for MoonLake Immunotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MoonLake Immunotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
